CVM

CVM - CEL-SCI Corp

SPECULATIVE BUYAWAIT ENTRYHealthcare · Biotechnology2026-08-01Updated todayUSD 1.16

Conviction

out of 100

Executive Summary

CEL-SCI Corporation (CVM) is a clinical-stage biotechnology company developing Multikine (leukocyte interleukin-2), an investigational immunotherapy candidate directed at neoadjuvant treatment of head and neck squamous cell carcinoma. The company is incorporated in Colorado and headquartered in Vienna, Virginia, and remains pre-revenue, reliant on capital markets to fund its development programmes rather than product sales. The Multikine programme has been in development for many years and represents the entirety of CEL-SCI's clinical pipeline; no marketed products are currently generating revenue.

The investment case rests on near-term execution of the Confirmatory Registration Study for Multikine and the recently disclosed Saudi Arabian licensing partnership, which together constitute the principal hard catalysts. The primary near-term catalyst is the planned submission seeking accelerated approval based on early tumour response data, with the 212-patient confirmatory study expected to commence enrolment. The key risk is ongoing cash consumption and the likelihood of further equity issuance at depressed share prices, which has already compressed the stock from a 52-week high of USD13.48 to USD1.16.

SPECULATIVE BUY. Conviction Score: 49/100. The view would upgrade to a higher-conviction Buy on confirmation of Multikine accelerated approval pathways and a non-dilutive funding event, and would downgrade to Sell on failure to commence enrolment in the confirmatory study or a material adverse event in clinical read-outs.

Business Model

CEL-SCI is a single-asset, clinical-stage developer with no recurring revenue stream. The company's economic model is structured around advancing Multikine through pivotal-stage clinical development, with the intention of either commercialising the product directly in select territories or licensing rights to regional partners in exchange for upfront payments, milestones, and royalties. Customers in this model are not yet end-patients but rather licensing counterparties and, ultimately, treating oncology centres that would administer the regimen if approved.

As CEL-SCI has no approved product, the income statement is dominated by research and development spend and general and administrative costs, with no gross margin to analyse. In the second quarter of fiscal 2026, research and development expenses were USD3.8 million and the reported quarterly loss was USD5.5 million on a Business Wire basis, while an Associated Press snapshot cited a USD10.9 million loss; these figures reflect the typical cost structure of a small-cap clinical-stage biotech, with the variance likely attributable to the inclusion or exclusion of non-cash items. The company has historically funded operations through equity issuances, most recently a public offering that raised approximately USD7.2 million in gross proceeds, as disclosed in a company announcement.

There is no meaningful competitive moat in commercial terms given the absence of revenue. What competitive position exists is centred on the Multikine regulatory designations, including prior FDA orphan drug designation for neoadjuvant therapy in squamous cell carcinoma of the head and neck, and on accumulated clinical data across earlier trials. Until pivotal data reads out and a commercial pathway is clarified, the company's enterprise value is effectively a call option on Multikine's regulatory outcome rather than a cash-flow-generating business.

Financial Snapshot

Price

USD 1.16

Market Cap

USD 20.3m

52w High

USD 13.48

52w Low

USD 0.89

Distance from 52wH

-91.4%

Beta

0.64

Avg Volume

380078

Currency

USD

Recent Catalysts

[2026-05-11] - CEL-SCI filed a Form 8-K with the SEC disclosing a current report event dated 11 May 2026, consistent with material corporate developments around the second-quarter reporting period. Source: SEC EDGAR (Form 8-K, filed 14 May 2026).

[2026-05-13] - A second Form 8-K was filed with the SEC, dated 13 May 2026, covering additional current-report disclosures in the run-up to the fiscal second-quarter release. Source: SEC EDGAR (Form 8-K, filed 13 May 2026).

[2026-05-18] - CEL-SCI reported fiscal second-quarter 2026 results, disclosing research and development expenses of USD3.8 million for the three months ended 31 March 2026 versus USD4.0 million in the prior-year period, alongside the plan to seek accelerated approval based on early tumour response data and the 212-patient Confirmatory Registration Study. Source: Business Wire press release, 18 May 2026.

[Q2 fiscal 2026] - The company closed a public offering generating approximately USD7.2 million in gross proceeds, providing near-term operating runway but also confirming the dilutive funding pattern typical of clinical-stage biotechs. Source: Company announcement via MissionIR syndication.

[Recent disclosure] - A licensing agreement with a Saudi Arabian pharmaceutical partner for Multikine was disclosed and characterised as imminent, providing a potential ex-United States commercial pathway. Source: Company press release as carried by stock-titan.net.

Thesis Evaluation

Bull Case (16% weight)

Multikine clears the planned accelerated-approval submission based on early tumour response data, enrolment in the 212-patient Confirmatory Registration Study commences on schedule, and the Saudi licensing agreement converts into upfront cash and milestone payments that materially extend runway without further dilution. Insider buying of approximately 300,000 shares by the CEO-linked parties and the prior FDA orphan drug designation underpin a credible regulatory runway. Price target: USD3.50, 12-month horizon.

Base Case (48% weight)

The confirmatory study enrols on a measured timeline, the Saudi licence progresses with modest upfront consideration, and the company executes one or two further dilutive financings to bridge to interim data, leaving the share price range-bound. The narrowed quarterly loss supports cost discipline but pre-revenue status limits re-rating absent a hard regulatory or partnership catalyst. Price target: USD1.40, 12-month horizon.

Bear Case (36% weight)

Persistent cash burn forces a discounted equity raise that pressures the share price below the USD1.00 area, enrolment in the confirmatory study slips materially, or interim Multikine data disappoints and the accelerated-approval pathway is closed off. In that scenario, the stock revisits or breaches the 52-week low of USD0.89. Price target: USD0.70, 12-month horizon.

Weighted conviction:Bull (16%) x 100 + Base (48%) x 62 + Bear (36%) x 10 = 49/100. SPECULATIVE BUY.

Key Risks

Clinical and regulatory risk on Multikine: The Multikine programme may fail to demonstrate sufficient efficacy or safety in the confirmatory study, closing off the accelerated-approval pathway and rendering the equity story materially impaired. Estimated probability: 35%. Impact: severe.
Dilution and going-concern financing risk: With a USD5.5 million quarterly loss and a history of equity issuance, CEL-SCI is likely to require additional capital that may be raised at depressed prices, materially diluting existing shareholders. Estimated probability: 70%. Impact: severe.
Single-asset concentration: The company's enterprise value is essentially a derivative of Multikine alone, leaving no portfolio diversification to absorb setbacks in the lead programme. Estimated probability: high by construction. Impact: severe.
Liquidity and share-price risk: The stock trades near its 52-week low of USD0.89 and well below its 52-week high of USD13.48, signalling thin liquidity and elevated volatility that can amplify downside in adverse scenarios. Estimated probability: ongoing. Impact: moderate.
Partnership execution risk on Saudi licence: The recently disclosed Saudi Arabian licensing arrangement may not convert into signed, funded terms on the expected timetable, removing a near-term cash and credibility catalyst. Estimated probability: 40%. Impact: moderate.
Going-concern and audit-flag risk: Recurring losses, negative P/E of -0.35x and reliance on capital markets raise the probability of a going-concern qualification in future audited financial statements, which can itself trigger forced selling. Estimated probability: 30%. Impact: severe.

Who Should Own It / Avoid It

Ideal for: experienced, high-risk-tolerance investors with a multi-year horizon of at least 18 to 24 months, comfortable with binary clinical and regulatory outcomes, and able to tolerate significant mark-to-market drawdowns of 50 percent or more; the position should be sized as a small satellite allocation within a diversified healthcare or small-cap portfolio, and is unsuitable for income-seeking investors or those requiring near-term liquidity.

Avoid if: you require positive cash flow, dividend payments, or a low-volatility profile; you are unable to stomach further dilutive financings at lower share prices; you need the capital within 12 months; or you are a novice investor without the time to monitor FDA correspondence, SEC filings, and clinical-trial enrolment updates specific to Multikine.

Recommendation

SPECULATIVE BUY - 49/100. The Speculative Buy tier reflects an asymmetric setup where a hard regulatory or licensing catalyst on Multikine could materially re-rate the equity from its current USD1.16 print, but where the same setup carries a high probability of further dilutive financing that limits upside in the base case and creates meaningful downside in the bear case. The call would upgrade to a higher-conviction Buy on commencement of enrolment in the 212-patient confirmatory study, a non-dilutive funding event, or conversion of the Saudi licence into cash terms, and would downgrade to Sell on failure to commence enrolment, an interim data disappointment, or a going-concern qualification in audited financials. At the current price of $1.16 the shares trade above our buy ceiling of $0.93: the thesis is credible but the price is not - new positions only below that level.

The probability-weighted value across our three scenarios is $1.48, 28% above the current price of $1.16 - the market has not yet priced our probability-weighted view. Levels below are derived from the scenario targets and probabilities above, not from percentage offsets to today's price.

BUY

below $0.93 - below this level the upside to the base-case target ($1.40) is at least 2x the downside to the bear case ($0.70), the minimum risk/reward we require before committing new capital.

HOLD

between $0.93 and $1.40 - the base case is not yet fully priced, so existing holders are paid to wait, but new money gets no margin of safety in this zone.

REDUCE

above $1.40 - at this level the base case is fully reflected in the price and anything beyond it is paying for a bull scenario we weight at 16%.

SELL

if A material adverse event or interim futility analysis in the Multikine confirmatory study, or failure to commence enrolment in the 212-patient study within the announced timeline, would invalidate the investment thesis regardless of price, regardless of price - the bear target of $0.70 is the backstop, not an arbitrary percentage stop.

Conviction Trend

Latest conviction: 49/100. Trend versus prior report: Down.

Report date	Conviction
2026-08-01	29
2026-07-25	49
2026-06-28	62

See the trade-card view →

Sources

Market data: DYOR HQ proprietary market data workflow.

Public sentiment and news flow: Company press releases distributed through Business Wire and carried by financial news outlets, syndicated small-cap investor news services, and public news flow relating to the fiscal second-quarter 2026 earnings release and the Saudi licensing disclosure; no internal data tools are referenced.

Primary source types: SEC filings on EDGAR (Form 8-K dated 11 May 2026 and Form 8-K dated 13 May 2026), company press releases, company investor relations materials, and third-party financial news reporting on the fiscal second-quarter 2026 results and capital-markets activity.

Key sources

Data correct as of 2026-08-01.